54.85
-0.75 (-1.35%)
| Penutupan Terdahulu | 55.60 |
| Buka | 55.61 |
| Jumlah Dagangan | 837,368 |
| Purata Dagangan (3B) | 8,723,204 |
| Modal Pasaran | 21,752,748,032 |
| Harga / Jualan (P/S) | 11.05 |
| Harga / Buku (P/B) | 2.50 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 1 May 2026 |
| Margin Keuntungan | -105.67% |
| Margin Operasi (TTM) | -972.22% |
| EPS Cair (TTM) | -8.73 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -35.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 7.40% |
| Nisbah Semasa (MRQ) | 4.22 |
| Aliran Tunai Operasi (OCF TTM) | -3.05 B |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -3.20 B |
| Pulangan Atas Aset (ROA TTM) | -15.84% |
| Pulangan Atas Ekuiti (ROE TTM) | -29.34% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Moderna, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | -0.50 |
|
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 7.28% |
| % Dimiliki oleh Institusi | 73.67% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Theleme Partners Llp | 31 Dec 2025 | 8,081,810 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 69.00 (Piper Sandler, 25.80%) | Beli |
| Median | 38.00 (-30.72%) | |
| Rendah | 30.00 (RBC Capital, -45.31%) | Pegang |
| Purata | 43.75 (-20.24%) | |
| Jumlah | 1 Beli, 3 Pegang | |
| Harga Purata @ Panggilan | 45.52 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Piper Sandler | 23 Feb 2026 | 69.00 (25.80%) | Beli | 50.29 |
| Evercore ISI Group | 17 Feb 2026 | 35.00 (-36.19%) | Pegang | 43.93 |
| Goldman Sachs | 17 Feb 2026 | 41.00 (-25.25%) | Pegang | 43.93 |
| RBC Capital | 17 Feb 2026 | 30.00 (-45.31%) | Pegang | 43.93 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 06 Mar 2026 | CNBC | FDA reversals leave investors worrying about the fates of other experimental drugs |
| 11 Feb 2026 | CNBC | Moderna says FDA refuses to review its application for experimental flu shot |
| 04 Feb 2026 | Pengumuman | Defiance Launches MRNX: The First Daily 2X Long ETF for Moderna, Inc. |
| 30 Jan 2026 | Pengumuman | Dr. David Berman to Join Moderna as Chief Development Officer |
| 29 Jan 2026 | Pengumuman | Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic (mRNA-3927) |
| 27 Jan 2026 | Pengumuman | Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks |
| 26 Jan 2026 | Pengumuman | Moderna to Report Fourth Quarter 2025 Financial Results on Friday, February 13, 2026 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |